Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: Role of α2-adrenoceptor antagonism

Neuropsychopharmacology

Volumn 17, Issue 1, 1997, Pages 44-55

  Hertel, Peter ^a   Nomikos, George G ^a   Schilström, Björn ^a   Arborelius, Lotta ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dorsal raphe nucleus; Electrophysiology; Frontal cortex; Microdialysis; Neuroleptic drugs; Serotonin

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMPEROZIDE; CLOZAPINE; HALOPERIDOL; HOMOVANILLIC ACID; IDAZOXAN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 2A ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL PHENOMENA; CONTROLLED STUDY; DEPRESSION; DIALYSATE; DORSAL RAPHE NUCLEUS; DRUG ANTAGONISM; DRUG MECHANISM; FRONTAL CORTEX; INTRACEREBRAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOIDISM; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SINGLE UNIT ACTIVITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; CEREBRAL CORTEX; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; IDAZOXAN; MALE; PIPERAZINES; PYRIDINES; RAPHE NUCLEI; RATS; RISPERIDONE; SEROTONIN;

EID: 0030911562     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(97)00002-X     Document Type: Article

References (62)

1. Aghajanian GK, Wang RY, Baraban J (1978): Serotonergic and non-serotonergic neurons of the dorsal raphe: Reciprocal changes in firing induced by peripheral nerve stimulation. Brain Res 153:169-175
2. Aghajanian GK (1995): Electrophysiology of serotonin receptor subtypes and signal transduction pathways. In Bloom FE, Kupfer DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, pp. 451-460
3. 1A receptor antagonist (S)-UH-301 blocks the (R)-8-OH-DPAT-induced inhibition of serotonergic dorsal raphe cell firing in the rat. J Neural Transm 96:179-186
4. Baraban JM, Aghajanian GK (1980): Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonist. Neuropharmacology 19:355-363
5. 2 receptor blocking agent. Curr Ther Res 40:492-499
6. Borison RL, Pathiraja PA, Diamond BI, Meibach RC (1992): Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 28:213-218
7. Carboni E, Di Chiara G (1989): Serotonin release estimated by transcortical dialysis in freely moving animals. Neuroscience 32:637-645
8. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40
9. Claghorn J, Honigfeld G, Abuzzahab FS, Wans R, Steinbook R, Tuason V, Klerman G (1987): The risk and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7:377-384
10. 2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol Psychiatry 29:629-634
11. Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS (1991): Mechanisms of action of atypical antipsychotic drugs: Implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4:121-156
12. 2-adrenoceptors. Br J Pharmacol 78:489-505
13. 2-adrenoceptor subtypes. Naunyn-Schmiedebergs Arch Pharmacol 353:391-399
14. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76
15. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
16. Ferré S, Artigas F (1995): Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism. Neurosci Lett 187:61-64
17. 1A receptor antagonist. Behav Brain Res 73:337-353
18. 2-adrenoceptors on rat central neurons. Eur J Pharmacol 105:265-272
19. Gallager DW, Aghajanian GK (1976): Effect of antipsychotic drugs on the firing of dorsal raphe cells. I. Role of adrenergic system. Eur J Pharmacol 39:341-355
20. Garratt JC, Crespi F, Mason R, Marsden CA (1991): Effects of idazoxan on dorsal raphe 5-hydroxytryptamine neuronal function. Eur J Pharmacol 193:87-93
21. 2 receptor blockers in the treatment of chronic schizophrenia. Clin Neuropharmacol 9:325-327
22. Gelders YG (1989): Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiatry 155:33-36
23. Gerlach J, Peacock L (1995): New antipsychotics: The present status. Int Clin Psychopharmacol 10:39-48
24. Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E (1995): A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 117:417-423
25. Goldman MB, Janecek HM (1990): Adjunctive fluoxetine improves global function in chronic schizophrenia. J Neuropsychiatr 2:429-431
26. Göthert M, Huth H, Schlicker E (1981): Characterization of the receptor subtype involved in alpha-adrenoceptor-mediated modulation of serotonin release from rat brain cortex slices. Naunyn-Schmiedebergs Arch Pharmacol 317:199-203
27. 2-Adrenoceptor antagonism may contribute to the atypical properties of risperdone: Experimental support for the Nutt case. J Psychopharmacol 9:281-283
28. Hernandez L, Hoebel BG (1989): Haloperidol given chronically decreases basal dopamine in the prefrontal cortex more than the striatum or nucleus accumbens as simultaneously measured by microdialysis. Brain Res Bull 22:763-769
29. Hertel P, Nomikos GG, Iurlo M, Svensson TH (1996): Risperidone: Regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology 124:74-86
30. 2 antagonistic properties. J Pharmacol Exp Ther 244:685-693
31. Kane J, Honigfeld G, Singer J, Meltzer HY (1988): Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789-796
32. 1A receptors. Eur J Pharmacol 260:79-83
33. 2 antagonist. Mol Pharmacol 27:600-611
34. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988): Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-670
35. Leysen JE, Janssen PFM, Gommeren W, Wynants J, Pauwels PJ, Janssen PAJ (1992): In vitro and in vivo receptor binding and effects on monoamine turnover in rat brains regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 41:494-508
36. 2 receptors. Psychopharmacology 112:S40-S54
37. Litman RE, Su TP, Potter WZ, Hong WW, Pickar D (1996): Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia: Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 168:571-579
38. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther 265:498-508
39. 2-adrenoceptor subtypes. Naunyn-Schmiedebergs Arch Pharmacol 345:410-416
40. McQuade R, Sharp T (1995): Release of cerebral 5-hydroxytryptamine evoked by electrical stimulation of the dorsal and medial raphe nuclei: Effect of a neurotoxic amphetamine. Neuroscience 68:1079-1088
41. i values. J Pharmacol Exp Ther 251:238-246
42. Meltzer HY, Nash JF (1991): Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587-604
43. Moore RY, Halaris AE, Jones BE (1978): Serotonin neurons of the midbrain raphe: Ascending projections. J Comp Neurol 180:417-438
44. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC (1992): Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striaturn. Neuropsychopharmacology 7:7-14
45. 2 adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J Psychoparmacol 8:193-195
46. 3 mediated control of dopaminergic function. Psychopharmacology 112:60-67
47. Paxinos G, Watson C (1986): The Rat Brain in Stereotaxic Coordinates. Sydney, Australia, Academic Press
48. 2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 273:273-279
49. Schotte A, Janssen PFM, Megens AAHP, Leysen JE (1993): Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 631:191-202
50. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996): Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 124:57-73
51. Seeman P, Lee T, Chau-Wong M, Wong K (1976): Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719
52. Seeman P (1980): Brain dopamine receptors. Pharmacol Rev 32:229-313
53. Silver H, Nassar A (1992): Fluvoxamine improves negative symptoms in treated chronic schizophrenia: An add-on double-blind, placebo-controlled study. Biol Psychiatry 31:698-704
54. Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, Di Rosa AE, Caputi AP (1994): Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 9:281-285
55. Starke K, Göthert M, Kilbinger H (1989): Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69:864-989
56. 2 receptor binding study of risperidone and haloperidol. Pharmacol Biochem Behav 47:553-557
57. 2 receptor occupancy. Neuropsychopharmacology 12:57-64
58. Svartengren J, Simonsson P (1990): Receptor binding properties of amperozide. Pharmacol Toxicol 66:8-11
59. Svensson TH, Bunney BS, Aghajanian GK (1975): Inhibition of both noradrenergic and serotonergic neurons in brain by the α-adrenergic agonist clonidine. Brain Res 92:291-306
60. Van Wielinck PS, Leysen JE (1983): Choice of neuroleptics based on in vitro pharmacology. J Drug Res 8:1984-1997
61. Vandermaelen CP, Aghajanian GK (1983): Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly in rat brain slices. Brain Res 289:109-119
62. Waters N, Pettersson G, Carlsson A, Svensson K (1989): The putatively antipsychotic agent amperozide produces behavioural stimulation in the rat: A behavioural and biochemical characterization. Naunyn-Scmiedebergs Arch Pharmacol 340:161-169